- €6.65bn
- €7.52bn
- $2.09bn
Brief: Qiagen Says Q1 Adjusted EPS $0.55
Becton Dickinson in talks with Thermo Fisher, Danaher to divest life sciences unit, FT reports (updated)
Brief: Qiagen Takes Legal Action To Defend Quantiferon Intellectual Property
Brief: Qiagen Strengthens Global Bioinformatics Leadership With New Data Center In Australia/Asia-Pacific Region
Brief: Qiagen CFO: If Situation Stabilizes, There Is Upside Potential For 2025 Outlook
Brief: Qiagen Sees 2025 Outlook For About 4% CER Sales Growth
US FDA approves Amgen's colorectal cancer therapy
Brief: Qiagen Announces Details For Completion Of Synthetic Share Repurchase Of Up To Approximately $300 Million
Brief: Qiagen To Return About $300 Mln To Shareholders Through Synthetic Share Repurchase
Brief: Qiagen Secures U.S. Clearance For First Qiastat-Dx Mini Gastrointestinal Panel To Support Year-Round Outpatient Care
Top of the Street: European telecoms, real estate, Qiagen, Ashtead
Qiagen rises after Q3 beat, profit outlook hike
Diagnostics firm Qiagen reports rise in third-quarter revenue
Brief: Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics
Brief: Qiagen Receives FDA Clearance For Qiastat-Dx Mini Panel
Europe Research Roundup: Ashmore, Biomerieux, Diasorin
Brief: QIAGEN Expands Automated Liquid Biopsy Portfolio To Enhance Oncology, Prenatal Care And Organ Transplant Applications
Brief: QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
Brief: PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples